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Abstract
Background: The aim of the present cross-sectional study was to assess possible associations between
osteopontin (OPN), and thrombin-cleaved (N-half) OPN, and nephropathy and coronary artery disease (CAD) in
patients with type 2 diabetes mellitus (T2DM).
Methods: Plasma levels of OPN, N-half OPN, and high-sensitivity C-reactive protein (hsCRP) were determined in
301 diabetic patients with (n = 226) or without (n = 75) angiographically documented CAD (luminal diameter
narrowing >50%), as well as in 75 non-diabetic controls with normal angiography. The estimated glomerular
filtration rate (eGFR) was calculated in all patients.
Results: Plasma levels of OPN and hsCRP were significantly higher in patients with T2DM compared with controls.
In addition, there was a higher occurrence of moderate renal insufficiency and lower eGFR in patients with T2DM
(all P < 0.01). T2DM patients in whom OPN levels were greater than the median value had higher serum creatinine
levels, a greater prevalence of mild or moderate renal insufficiency, a higher incidence of CAD, and lower eGFR (all
P < 0.05) than T2DM patients in whom OPN levels were the same as or lower than the median value. However,
there were no differences in these parameters when patients were stratified according to plasma N-half OPN levels.
Furthermore, there was a significant correlation between OPN, but not N-half OPN, and the severity of
nephropathy and CAD in diabetes. After adjustment for potential confounders and treatments, multiple linear
regression analysis demonstrated an independent association between OPN, but not N-half OPN, and eGFR.
Multivariate logistic regression revealed that higher OPN levels conferred a fourfold greater risk of renal
insufficiency and CAD in patients with T2DM.
Conclusions: The results of the present study demonstrate that there is an independent association between
plasma levels of OPN, but not N-half OPN, and the presence and severity of nephropathy and CAD in diabetes.
Background
Micro- and macro-vasculopathies, such as nephropathy
and coronary artery disease (CAD), respectively, are
common in diabetes and constitute the major causes of
death for these patients [1,2]. Proinflammatory cytokines
play a critical role in the pathogenesis of diabetic com-
plications through various biochemical and cellular
pathways [1,3-5]. Full-length osteopontin (OPN), a
macrophage chemotactic protein, was originally identi-
fied as a mediator involved in bone remodeling, chronic
inflammatory and autoimmune diseases [6,7], and subse-
quently demonstrated to play an important role in the
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development of cardiovascular diseases [6,8]. OPN was
synthesized by monocytes/macrophages, endothelial
cells, and vascular smooth muscle cells, and proved to
express in neointima and calcified atheromatous plaque
[6,9]. In contrast, an OPN neutralizing antibody could
inhibit rat carotid neointimal formation after endothelial
denudation [10]. Clinically, a significant association has
been demonstrated, independent of traditional risk fac-
tors, between plasma OPN levels and atherosclerotic
plaque formation in general patients [11,12]. Further-
more, OPN expression has been shown to be upregu-
lated in the vascular wall of diabetic patients and
diabetic animal models, which might be induced by high
glucose and advanced glycation endproduct [9,13-15]. In
kedney, OPN has also been identified in glomerular
mesangial cells, podocytes, and endothelial cells [16-18].
Microarray analyses of diabetic versus normal kidneys
identified OPN as one of the major genes upregulated
in humans with diabetic nephropathy and in mice with
either type 1 diabetes or the type 2 db/db model of dia-
betes [19]. OPN knockout mice were protected from
diabetes-induced albuminuria and mesangial expansion
[18]. A strong correlation between higher OPN levels
and more severe diabetic albuminuria and glomerulo-
sclerosis has been demonstrated in various models of
diabetic nephropathy [19,20]. All these observations sug-
gested a possible role of OPN in accelerated atherogen-
esis and the development of renal disease in diabetes
mellitus.
Structurally, OPN contains several cell-interacting
domains, as well as protease-cleavage sites, that may
be important in regulating its activity. These domains
include: (i) an arginine-glycine-aspartate (RGD)-
containing domain that interacts with cell surface
integrins avb3, avb1, avb5, and a8b1, promoting the
migration and/or growth potential of lymphocytes,
macrophages, endothelial cells, and vascular smooth
muscle cells; and (ii) a cryptic serine-valine-valine-
tyrosine-glutamate-leucine-arginine (SVVYGLR)-con-
taining domain cleaved by thrombin that interacts with
a9b1, a4b1, and a4b7 integrins and mediates cell
adhesion to the NH2-terminal fragment of OPN, caus-
ing inflammation in an RGD-independent manner
[6,21,22]. Patients with diabetes often have a chronic
procoagulant state, as reflected by increased thrombin
activity and elevated circulating thrombin/anti-throm-
bin complexes [23-25]. Thrombin-cleaved (N-half)
OPN levels are elevated in the vitreous fluid of patients
with diabetic retinopathy [26], as well as in the syno-
vial fluid and plasma of patients with rheumatoid
arthritis [7,27], highlighting the possibility that this
cytokine may be involved in local inflammation.
Because diabetes per se is an inflammatory process
with increased cytokine levels and enhanced thrombin
activity in the vascular wall [1,23], in the present study
we tested the hypothesis that there may be an associa-
tion between both OPN and N-half OPN levels and
the presence and severity of nephropathy and CAD in
patients with type 2 diabetes mellitus (T2DM).
Methods
The study protocol was approved by the Ruijin Hospital
ethics committee. Written informed consent was obtained
from all patients prior to their inclusion in the study.
Study population
The present study was performed on 301 consecutive
diabetic patients (171 men and 130 women) undergoing
angiography for suspected CAD or percutaneous coron-
ary intervention (PCI) between June 2005 and October
2007. Patients with concomitant valvular heart disease,
cardiomyopathy, acute renal failure, acute and chronic
viral or bacterial infections, asthma, tumors, or connec-
tive tissue diseases, and those undergoing coronary artery
bypass surgery or on dialysis, were excluded from the
study. In addition, patients with acute coronary syn-
drome, in-stent restenosis or those with symptomatic
heart failure were excluded from the study. Patients with
type 1 diabetes mellitus were identified on the basis of
C-peptide measurements and were also excluded from
the study. T2DM was diagnosed using the following cri-
teria: (i) fasting plasma glucose levels ≥7.0 mmol/L on
two occasions; (ii) two 2-h postprandial plasma glucose
readings ≥11.1 mmol/L after a glucose load of 75 g; (iii)
two casual glucose readings ≥11.1 mmol/L; or (iv) treat-
ment with oral hypoglycemic drugs or parenteral insulin.
The clinical characteristics and risk factors for CAD were
recorded for each patient. Almost all T2DM patients
were receiving antidiabetic treatment and most were tak-
ing statins and angiotensin-converting enzyme (ACE)
inhibitors or angiotensin receptor blockers (ARBs).
Seventy-five consecutive non-diabetic patients (38
men, 37 women) who underwent coronary angiography
for suspected CAD but had normal coronary arteries
served as the control group. The professional activities
and diet styles of the control group were matched with
those of the diabetic patients. Liver and renal function
tests were normal.
To elucidate the relationship between OPN or N-half
OPN and nephropathy or CAD in diabetes, T2DM
patients were divided into two groups, those with higher
than median plasma values of OPN (235.0 ng/mL) and
N-half OPN (25.0 pmol/L) and those with median or
lower plasma values of OPN and N-half OPN. This was
done because the distribution of plasma values of OPN
and half-OPN is not normal.
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Coronary angiography
Selective coronary angiography was performed using a
femoral or radial artery approach by cardiologists
blinded to the study protocol. Significant CAD was diag-
nosed visually if the narrowing of the luminal diameter
of a major epicardial coronary artery was ≥50%. Patients
with significant CAD were further classified into those
with one-, two-, or three-vessel disease depending on
the number of coronary arteries involved. A ≥50% nar-
rowing of the left main coronary artery was considered
as two-vessel disease.
Biochemical investigations
Blood samples were collected from all patients before
coronary angiography and after an overnight fast. Plasma
OPN level was determined with a commercially available
ELISA kit (Human OPN assay kit, IBL, Gunma, Japan)
according to its protocol, which only detects full-length
OPN. The sensitivity for OPN was 3.33 ng/ml with an
intra- and inter-assay CV of <5% and <10%, respectively.
Plasma levels of N-half OPN were measured using an
ELISA kit (Human Osteopontin N-Half Assay Kit, IBL,
Gunma, Japan). In brief, 1:2 diluted testing samples were
incubated in the N-half OPN antibody pre-coated wells
at 37°C for 1 h. Following washing, 100 uL of labeled
OPN antibody solution was added into each well and
incubated for 30 min at 4°C. After washing, tetramethyl
benzidine was used as a coloring agent, and the absor-
bance at 450 nm was measured with an automatic ELISA
reader (Bio-Rad, Segrate, Italy). The intra- and inter-
assay coefficients of variation (CV) were <5% and <8%,
respectively, with a sensitivity 3.09 pg/L. Furthermore,
plasma levels high-sensitivity C-reactive protein (hsCRP)
were determined (Quantikine ELISA kits; R&D Systems,
Minneapolis, MN, USA). Estimated glomerular filtration
rate (eGFR) was calculated using the formula of the Mod-
ification of Diet in Renal Disease study group [26]. Mild,
moderate, and severe renal insufficiency was diagnosed
when the eGFR was <90, <60, and <30 mL/min per
1.73 m2, respectively.
Statistical analysis
All statistical analyses were performed using SPSS for
Windows 13.0 (SPSS Inc., Chicago, IL, USA). Unless
indicated otherwise, data are presented as frequencies or
percentages for categorical variables and as the mean
(±SD) or median (interquartile range) for continuous
variables. For categorical clinical variables, differences
between groups were evaluated with the Chi-squared
test. For continuous variables, normal distribution was
evaluated with the Kolmolgorov-Smirnov test. Variables
that were not normally distributed were log transformed
when necessary. Comparisons between groups were
made using analysis of variance for variables with a
parametric distribution. Correlations were evaluated by
calculating Spearman’s correlation coefficient. Multiple
linear regression analyses with eGFR and OPN as
dependent variables were used to assess independent
relationships. A multivariate logistic regression model
was constructed to assess the independent determinants
for a moderate decrease in eGFR, CAD and either of the




Compared with non-diabetic controls, T2DM patients
were older, had higher systolic and diastolic blood pres-
sures, higher triglyceride and fasting glucose levels, and
lower high-density lipoprotein-cholesterol levels. More
diabetic patients were receiving treatment with statins
and ACE inhibitors or ARBs than controls (Table 1).
OPN and N-half OPN levels in relation to nephropathy
and CAD
Compared with controls, diabetic patients had signifi-
cantly higher OPN (P < 0.001), hsCRP (P < 0.001), and
creatinine (P < 0.01) levels, were more likely to have
moderate renal insufficiency (P < 0.01), and had a lower
eGFR (P < 0.001; Table 2).
Serum creatinine and occurrence rate of mild or mod-
erate renal insufficiency were higher in T2DM patients
with OPN levels greater than the median compared
Table 1 Clinical characteristics and biochemical
assessments of study patients
Variable Control (n = 75) Diabetes (n = 301)
Men/Female (n) 38/37 171/130
Age (years) 56.7 ± 10.5 65.5 ± 9.7*
Smokers (%) 14 (18.7) 88 (29.2)
Hypertension (%) 6 (8.0) 252 (83.7)*
SBP (mmHg) 122 ± 15 136 ± 19*
DBP (mmHg) 75 ± 8 79 ± 11†
Hyperlipidemia (%) 25 (33.3) 196 (65.1)*
Triglyceride (mmol/L) 1.35 ± 0.65 2.08 ± 1.63*
Total cholestrol (mmol/L) 4.30 ± 0.80 4.47 ± 1.00
HDL-C (mmol/L) 1.33 ± 0.35 1.17 ± 0.31*
LDL-C (mmol/L) 2.49 ± 0.55 2.55 ± 0.82
Lipoprotein (a) (g/L) 0.23 ± 0.19 0.25 ± 0.20
Fast glucose (mmol/L) 4.85 ± 0.63 6.98 ± 2.56*
HbA1c (%) - 7.57 ± 1.35
ACEI or ARB (%) 7 (9.3) 234 (77.7)*
Statins (%) 17 (22.7) 237 (78.7)*
Data are given as either the number of patients (%), mean ± SD. *P < 0.001,
†P < 0.01 compared with the control group.
Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure;
HDL-C, high-density lipoprotein-cholesterol; LDL-C, low-density lipoprotein-
cholesterol; HbA1c, glycated hemoglobin; ACEI, angiotensin-converting
enzyme inhibitor; ARB, angiotensin II receptor blocker.
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with those with OPN levels lower than the median
(creatinine 90.3 ± 30.2 vs. 79.2 ± 19.5 μmol/L, respec-
tively (P < 0.001); mild renal insufficiency 78.8% vs.
63.6%, respectively (P < 0.01); and moderate renal insuf-
ficiency 21.9% vs 11.2%, respectively (P < 0.05)); in con-
trast, eGFR was higher in T2DM patients with OPN
levels below the median (84.1 ± 19.5 vs 75.5 ± 21.3 mL/
min per 1.73 m2; P < 0.001; Table 2). There were no
significant differences in creatinine levels, eGFR, and the
occurrence of renal insufficiency between groups strati-
fied according to N-half OPN values (Table 2). In addi-
tion, there was a negative correlation found between
OPN, but not N-half OPN, and eGFR in T2DM patients
(r = -0.258; P < 0.001; Figure 1A), as well as stepwise
increases in mean OPN concentrations in patients with
deteriorating renal function (237 ± 72, 268 ± 120, and
338 ± 203 ng/mL in T2DM patients with normal, mild,
moderate renal insufficiency, respectively; P < 0.001; Fig-
ure 1B). In the present study, the five T2DM patients
whose eGFR was <30 mL/min per 1.73 m2 had highest
plasma OPN levels (402 ± 141 ng/mL). However, there
was no difference in the percent of N-half OPN (N-half
OPN/OPN*100%) in T2DM patients with normal, mild
and moderate renal insufficiency (P = 0.65).
Patients with OPN concentrations greater than the
median value had a higher incidence of CAD than those
with OPN levels below the medium value (80.8% vs.
69.3%, respectively; P < 0.05), but differences were not
found for patient groups stratified according to N-half
OPN values (76.2% vs. 74.0%; P > 0.05; Table 2). Further-
more, in patients with T2DM, the presence and severity
of CAD were significantly associated with plasma OPN
(P = 0.002 and Ptrend = 0.002), but not with N-half OPN
levels (Figure 1C, D). In addition, the percent of N-half
OPN was similar in T2DM patients with and without
CAD (P = 0.55).
In T2DM patients, there was a positive correlation
between plasma OPN levels and hsCRP (r = 0.394; P <
0.001). After adjusting for age, the associations between
plasma OPN and hsCRP (r = 0.383; P < 0.001) remained
significant. However, N-half OPN did not correlate with
other variables in this study.
Multivariate regression analysis on nephropathy and CAD
in diabetes
Multiple linear regression analysis showed that after
adjustment for several potential confounding variables
in Model A, eGFR was independently correlated with
OPN (P = 0.002). In a similar analysis, when OPN was
used as a dependent variable in Model B after adjust-
ment for several potential confounding variables, inde-
pendent associations were found between OPN and
N-half OPN, hsCRP, and eGFR (all P < 0.01; Table 3).
Multiple logistic regression analysis revealed that
after adjustment for several potential confounding vari-
ables, the risk of a moderate reduction in eGFR, the
presence of CAD, and a moderate reduction in eGFR
or CAD increased more than fourfold (P = 0.006, P =
0.034, and P = 0.027, respectively) for OPN in the dia-
betic cohort (Table 4). Furthermore, eGFR was inde-
pendently associated with the presence of CAD (P =
0.026; Table 4).
Discussion
The present study demonstrated that plasma levels of
OPN, but not N-half OPN, are independently associated
with the presence and severity of nephropathy and CAD
in diabetes.



















Creatinine (μmol/L) 74.7 ± 14.6 84.8 ± 26.1† 79.2 ± 19.5 90.3 ± 30.2* 83.9 ± 27.3 85.8 ± 24.8
eGFR (mL/min/1.73 m2) 89.6 ± 20.3 79.8 ± 20.9* 84.1 ± 19.5 75.5 ± 21.3* 80.9 ± 20.2 78.6 ± 21.5
eGFR <90 mL/min/1.73 m2 (%) 45 (60) 206 (71.3) 91 (63.6) 115 (78.8)† 106 (72.6) 100 (69.9)
eGFR <60 mL/min/1.73 m2 (%) 2 (2.7) 48 (16.6)† 16 (11.2) 32 (21.9)‡ 19 (13.0) 29 (20.3)
CAD (%) - 226 (75.1) 104 (69.3) 122 (80.8)‡ 111 (74.0) 115 (76.2)
Inflammatory cytokines
OPN (ng/mL) 218 (190, 261) 235 (201, 284)* 201 (186, 218) 284 (258, 359)* 242 (212, 279) 226 (191, 286)
N-half OPN (pmol/L) 23.8 (18.9, 41.9) 25.3 (20.6, 34.9) 27.9 (20.8, 42.7) 23.8 (20.4, 31.4)† 20.6 (18.7, 22.3) 34.8 (29.3, 44.3)*
HsCRP (ng/mL) 150 (102, 330) 286 (139, 675)* 206 (130, 373) 426 (173,1049)* 285 (149, 629) 288 (130, 790)
Data are given as mean ± SD or the median (interquartile ranges), as appropriate. *P < 0.001, †P < 0.01, ‡P < 0.05 compared with the control group, the group
with OPN values below the median value and the group with N-half OPN values below the median, respectively.
Abbreviations: eGFR, estimated glomerular filtration rate; CAD, coronary artery disease; OPN, osteopontin; N-half OPN, Thrombin-cleaved N-half osteopontin;
hsCRP, high sensitive C-reactive protein.
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Relationship between plasma OPN levels and
nephropathy and CAD in diabetes
Previous studies have shown that advanced glycation
end-products and angiotensin II can stimulate OPN
synthesis by a variety of cells, including mesangial cells
and podocytes, and initiate local effects of cell spreading,
adhesion, and proliferation [28-30]. In rat models of
streptozotocin- or high-fat diet-induced diabetic nephro-
pathy, OPN expression is significantly upregulated in the
renal cortex and aorta [31,32], and increased OPN
expression is strongly correlated with severe diabetic
albuminuria and glomerulosclerosis [19,20]. In contrast,
OPN-knockout mice do not develop albuminuria in
response to lipopolysaccharide, and are protected from
diabetes-induced mesangial expansion [18]. In patients
with diabetic nephropathy, OPN expression is closely
related to the degree of cortical interstitial scarring [33].
Yamaguchi et al. found that plasma OPN levels were
increased in diabetic patients with renal failure [34]. In
the present study, all patients had cardiovascular risk
Figure 1 Association between plasma osteopontin (OPN) levels and renal insufficiency and coronary artery (CAD) disease in all
diabetic patients. (A) Scatter plot showing the relationship between OPN and estimated glomerular filtration rate (eGFR) in the diabetic
population. OPN concentrations were log-transformed and R represents Pearson’s correlation coefficient. (B) Plasma OPN levels in patients with
different renal function stratified according to eGFR. Data are the mean ± SEM. Differences among groups were analyzed by one-way ANOVA
followed by post hoc analysis (with Bonferroni’s correction). (C, D) Relationship between plasma OPN levels and the presence (C) and severity (D)
of CAD in diabetes. Data are the mean ± SEM.
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factors and had been hospitalized for diagnostic angio-
graphy and/or PCI. We found that plasma OPN concen-
trations were proportional to the severity of renal
dysfunction and were an independent risk factor for the
presence and severity of renal insufficiency, suggesting
that OPN may play a pivotal role in the development of
diabetic nephropathy in these high-risk patients. Con-
versely, the presence of renal insufficiency could lead to
elevated plasma OPN concentrations, forming a vicious
cycle that exaggerates diabetic nephropathy and
atherosclerosis.
Plasma OPN levels have been shown to be correlated
with the angiographic severity of CAD, independent of
conventional risk factors [12], and have been identified
as a potential marker of atherosclerotic disease progres-
sion and adverse cardiovascular outcome in patients
with stable angina [11]. Consistent with previous obser-
vations [35], we found in the present study that OPN
was closely associated with hsCRP levels independent of
age, suggesting that OPN, as an impaortant inflamma-
tory cytokine, may aggravate the inflammation status in
diabetes mellitus. In addition, we demonstrated a signifi-
cant association between plasma OPN levels and the
presence and severity of CAD in diabetic patients, indi-
cating that OPN may be critically involved in the
inflammatory processes that take place within the vascu-
lar wall in diabetes.
Relationship between plasma concentrations of N-half
OPN and nephropathy and CAD in diabetes
In vitro studies have reported that the N-terminal frag-
ments of OPN generated by both thrombin cleavage and
matrix metalloproteinase (MMP) cleavage induce
enhanced adhesion compared with the effects of full-length
OPN. This appears to be due mostly to increased activity
of the RGD site, perhaps an indication of conformational
change resulting in higher affinity binding [6]. In a model
of rheumatoid arthritis, an antibody specifically neutraliz-
ing only the SLAYGLR domain of mouse OPN (homolo-
gous to the SVVYGLR of human OPN) greatly abrogated
monocyte migration towards the thrombin-cleaved form
of OPN and inhibited the proliferation of synovial cells,
bone erosion, and inflammatory cell infiltration in arthritic
joints [21]. Another study showed that the SVVYGLR
sequence induces pro-MMP9 expression in isolated vascu-
lar smooth muscle cells, as well as in aortas from diabetic
mice [36]. Clinically, N-half OPN levels are elevated in the
synovial fluid, urine, and plasma of patients with rheuma-
toid arthritis [7,27,35], as well as in the vitreous fluid of
those with diabetic retinopathy [26], indicating that this
cytokine is involved in local inflammation. Because dia-
betes per se is an inflammatory process with increased
cytokine levels and enhanced thrombin activity in the vas-
cular wall [23], we hypothesized that N-half OPN may be
associated with the development and severity of nephropa-
thy and CAD in this setting. Unexpectedly, there was no
association between N-half OPN and CAD or hsCRP in
diabetic patients. This may be due to the relatively lower
concentrations of N-half OPN compared with full-length
OPN in plasma (the percent of N-half OPN/OPN was no
more than 1%). Alternatively, N-half OPN may exist pre-
dominantly in local tissue rather than in the circulation.
Further studies are warranted to examine the role of circu-
lating and local vascular N-half OPN in the pathogenesis
of diabetic nephropathy and atherosclerosis.
Table 3 Multiple linear regression analysis of
relationships between selected variables and estimated
glomerular filtration rate or osteopontin
Variable b SEM P
Model A: Dependent variable eGFR
Age -0.889 0.127 <0.001
OPN -11.967 3.823 0.002
Model B: Dependent variable OPN
N-half OPN -0.136 0.027 <0.001
hsCRP 0.103 0.017 <0.001
eGFR -0.003 0.001 0.002
In addition to the significant covariables shown in the table, Model A also
included sex, cigarette smoking, systolic blood pressure (SBP), total
cholesterol, triglyceride, lipoprotein (a), fasting glucose, use of angiotensin
receptor blockers (ARBs) or angiotensin-converting enzyme inhibitors (ACEI),
use of statins, log-transformed thrombin-cleaved osteopontin (N-half OPN),
and log-transformed high-sensitivity C-reactive protein (hsCRP). Model B
included sex, age, cigarette smoking, SBP, total cholesterol, triglyceride,
lipoprotein (a), fasting glucose, use of ARBs or ACEI, and the use of statins.
Table 4 Determinants for presence of an estimated
glomerular filtration rate <60 mL/min per 1.73 m2 and
coronary artery disease
Variable Odds ratio 95% Confidence interval P
Model A: Dependent variable moderate reduction in eGFR
Age 1.08 1.04-1.14 0.001
OPN 4.58 1.55-13.59 0.006
Model B: Dependent variable CAD
Sex 2.29 1.10-4.79 0.028
Statins 5.14 2.52-10.48 <0.001
OPN 4.30 1.12-16.54 0.034
eGFR 0.20 0.05-0.82 0.026
Model C: Dependent variable moderate reduction in eGFR or CAD
Age 1.06 1.02 - 1.11 0.002
Statins 4.62 2.29 - 9.35 <0.001
OPN 4.49 1.18 - 17.05 0.027
Models A and C also included sex, cigarette smoking, systolic blood pressure
(SBP), total cholesterol, triglyceride, lipoprotein (a), fasting glucose, use of
angiotensin receptor blockers (ARBs) or angiotensin-converting enzyme
inhibitors (ACEI), use of statins, log-transformed thrombin-cleaved osteopontin
(N-half OPN), and log-transformed high-sensitivity C-reactive protein (hsCRP).
Model B also included cigarette smoking, SBP, total cholesterol, triglyceride,
lipoprotein (a), fasting glucose, use of ARBs or ACEI, log-transformed N-half
OPN, log-transformed hsCRP, and log-transformed estimated glomerular
filtration rate (eGFR).
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Clinical relevance of OPN in diabetes
Type 2 diabetes is an independent risk factor for cardio-
vascular diseases and a CAD equivalent [2,37]. Its com-
plications mainly include diabetic nephropathy,
atherosclerosis and retinopathy [1]. Although hypoglyce-
mic agents can control blood glucose, current treatment
is still not sufficient to prevent the development of dia-
betic complications [37]. Therefore, in these high-risk
patients, early detection and effective prevention of the
complications become an important issue. In the present
study, we found that plasma OPN level, but not N-half
OPN parallels with the severity of nephropathy and
CAD in diabetes, suggesting that an increased plasma
OPN level may be used as an indicator for screening
diabetic vasculopathy. Furthermore, since basic research
showed that OPN contributes to the development of
nephropathy and atherosclerosis in diabetes [10,18-20],
inhibition of OPN may become a novel therapeutic
strategy for these paitents.
Study limitations
There are several limitations to the present study. First,
the present study was a cross-sectional design; thus, our
results reflect only the association between OPN or
N-half OPN levels and prevalent rather than incident
atherosclerosis. Second, all subjects in the present study
were scheduled for coronary angiography and/or PCI,
and are thus likely to be more typical of a high-risk
patient group than the healthy population at large.
In conclusion, the present study indicates that plasma
concentrations of OPN, but not N-half OPN, are inde-
pendently associated with the presence and severity of
nephropathy and CAD in T2DM patients. Approaches
involving the inhibition of OPN signaling may prove
valuable therapeutic strategies for the prevention of dia-
betic complications and improved patient outcomes.
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